- Country: USA
- Summary: TECHNOLOGY/BUSINESS OPPORTUNITY Modified cyclodextrins to counteract the effects of fentanyl and related opioids
- UST Ref No: 116219684
- Deadline: 12 Apr 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: IL-13067
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
Opportunity:
Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration to further develop and commercialize its modified cyclodextrins to counteract the effects of fentanyl and related opioids.
Background:
Fentanyl is a powerful rapid-acting opioid used to treat patients to reduce their pain. It is 50 to 100 times more potent than morphine and heroin and according to the DEA is now the leading cause of death for Americans between the ages of 18 and 45. Due to this largely recognized fentanyl epidemic, there is a great need for treatment to counteract the effects of fentanyl for overdose cases.
Cyclodextrins (CDs), which are sugar molecules bound together in rings of various sizes, have been shown to be capable of sequestering fentanyl and its analogues. By binding to the fentanyl with its hollow central cavity, CDs can reduce its bioavailability, thus neutralizing the effects of the drug. Optimization of the central cavity of the cyclodextrin molecule is required for the binding of the fentanyl to be successful. For example, FDA approved drug, sugammadex, was found to bind to another drug rocuronium effectively, but with fentanyl, the affinity was relatively low. This was due to its large interior cavity that did not allow the opioid molecule to fit tightly within.
To optimize the affinity for fentanyl, LLNL researchers used a combined experimental and computational approach to screen for modified cyclodextrins that have suitable characteristics like appropriately sized central cavity that could enhanced their affinities for fentanyl and related analogues.
Description:
After screening at least 50 different cyclodextrins, LLNL researchers found that the drug Subetadex shows enhanced affinities for fentanyl an... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINTECHNOLOGY/BUSINESS OPPORTUNITY Modified cyclodextrins to counteract the effects of fentanyl and related opioids - USA Tender
The ENERGY, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for TECHNOLOGY/BUSINESS OPPORTUNITY Modified cyclodextrins to counteract the effects of fentanyl and related opioids. This tender is published on USARFP under UST Ref No: 116219684 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-04-12.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
